[HTML][HTML] Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB …
EV Low, MD Pathmanathan, SK Chidambaram… - International Journal of …, 2023 - Elsevier
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
Real world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk COVID-19 patients during Omicron BA. 4, BA. 5 and XBB subvariants …
EV Low, MD Pathmanathan… - … Journal of Infectious …, 2023 - europepmc.org
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB subvariants …
EV Low, MD Pathmanathan… - International Journal of …, 2023 - ijidonline.com
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB subvariants …
EV Low, MD Pathmanathan… - … journal of infectious … - pubmed.ncbi.nlm.nih.gov
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
[PDF][PDF] Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB …
EV Low, MD Pathmanathan… - … Journal of Infectious …, 2023 - researchgate.net
abstract Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days
in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a …
in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a …
Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during omicron BA. 4, BA. 5 and XBB subvariants …
EV Low, MD Pathmanathan, SK Chidambaram… - 2023 - cabidigitallibrary.org
Objective: To determine if nirmatrelvir-ritonavir 300 mg/100 mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …